Mark Tulli, MD
Interventional Cardiology · Gainesville, FLNPI 1265484257
Payments from drug & device makers
Across 230 payments — averaging $786.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$76K
- Boston Scientific$67K
- Abbott$33K
- Abiomed$1K
- Amgen$937
- Edwards Lifesciences$415
- plus $2K from 24 others
What the payments were for
- Consulting fees$1,31313%
- Grants$1231%
- Travel & lodging$9579%
- Food & beverage$7,99277%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 31 | $76,260 |
| Boston Scientific | 25 | $66,951 |
| Abbott | 47 | $33,016 |
| Abiomed | 8 | $1,024 |
| Amgen | 23 | $937 |
| Edwards Lifesciences | 5 | $415 |
| Boehringer Ingelheim | 15 | $302 |
| Acist Medical Systems, Inc. | 4 | $226 |
| Lexicon Pharmaceuticals, Inc. | 11 | $177 |
| Novartis | 8 | $159 |
| Shockwave Medical, Inc | 1 | $149 |
| Penumbra, Inc. | 4 | $146 |
| Johnson & Johnson | 5 | $143 |
| Stryker | 1 | $134 |
| E.r. Squibb & Sons, L.L.C. | 8 | $129 |
| Merck | 7 | $122 |
| Recor Medical Inc | 1 | $112 |
| AstraZeneca | 5 | $78 |
| Pfizer | 4 | $65 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $53 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $47 |
| Bayer | 2 | $40 |
| Silk Road Medical, Inc. | 2 | $36 |
| Angiodynamics, Inc. | 1 | $32 |
| Cardiva Medical, Inc. | 1 | $26 |
| Organogenesis Inc. | 1 | $26 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Cook Medical LLC | 1 | $14 |
| Bardy Diagnostics, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Xience V coronary stent system$1,112
- Impella$762
- Optis Coronary Imaging System$725
- Omnilink Elite vascular stent system$700
- Perclose ProGlide suture mediated closure system$613
- Repatha$592
- COREVALVE EVOLUT R$403
- 3F$233
- CoreValve Evolut$185
- FFRangio$150
- Vascular Lithotripsy$149
- AVVIGO Guidance System$138
- NAVITOR$137
- LIMFLOW SYSTEM$134
- RESOLUTE ONYX$134
- ONYX FRONTIER$131
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$129
- GENERAL - STENTS$124
- Edwards SAPIEN 3 Transcatheter Heart Valve$116
- PARADISE RENAL DENERVATION SYSTEM$112
How this compares
$180,860 in reported general payments places this provider in the 85th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 367 | $404,384 |
| EntrestoSacubitril/Valsartan | 155 | $164,037 |
| JardianceEmpagliflozin | 130 | $145,052 |
| Repatha SureclickEvolocumab | 163 | $102,885 |
| XareltoRivaroxaban | 114 | $93,759 |
| Praluent PenAlirocumab | 30 | $21,643 |
| FarxigaDapagliflozin Propanediol | 17 | $19,861 |
| MultaqDronedarone Hcl | 11 | $14,613 |
| NexletolBempedoic Acid | 12 | $5,582 |
| Metoprolol Succinate | 373 | $5,073 |
| Flecainide Acetate | 101 | $3,786 |
| Atorvastatin Calcium | 362 | $3,214 |
| Ranolazine ErRanolazine | 25 | $2,926 |
| Ezetimibe | 96 | $2,132 |
| ClopidogrelClopidogrel Bisulfate | 168 | $1,889 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $65 | $404,384367 claims |
| NovartisEntresto | $159 | $164,037155 claims |
| Boehringer IngelheimJardiance | $302 | $145,052130 claims |
| Johnson & JohnsonXarelto | $143 | $93,759114 claims |
| AstraZenecaFarxiga | $78 | $19,86117 claims |
| Sanofi-aventis U.S. LLCMultaq | $15 | $14,61311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Gainesville
- Arthur LeeGainesville$2M
- Amit BadiyeGainesville$449K
- Matheen KhuddusGainesville$423K
- R AndersonGainesville$238K
- Dominick AngiolilloJacksonville$4M
- Douglas SpriggsClearwater$3.2M
- Rakesh PrashadOcala$3.1M
- Aldo Martinez FleitesMiami Lakes$2.2M
- Rohit AminPensacola$2M
- Roberto CubedduNaples$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.